bluebird bio to Present at LEERINK Partners Global Healthcare Conference Read more about bluebird bio to Present at LEERINK Partners Global Healthcare Conference
LEERINK Partners Global Healthcare Conference Read more about LEERINK Partners Global Healthcare Conference
bluebird bio Announces Closing of Over-Allotment Option in Public Offering Read more about bluebird bio Announces Closing of Over-Allotment Option in Public Offering
36th Annual J.P. Morgan Healthcare Conference - Q&A Breakout Session Read more about 36th Annual J.P. Morgan Healthcare Conference - Q&A Breakout Session
36th Annual J.P. Morgan Healthcare Conference Read more about 36th Annual J.P. Morgan Healthcare Conference
bluebird bio to Present at Investor Conferences in January Read more about bluebird bio to Present at Investor Conferences in January
bluebird bio Announces Pricing of Public Offering of Common Stock Read more about bluebird bio Announces Pricing of Public Offering of Common Stock
bluebird bio Announces Proposed Public Offering of Common Stock Read more about bluebird bio Announces Proposed Public Offering of Common Stock
bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting Read more about bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobinTM Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting Read more about bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting